Shamsuddin Virani

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Barriers to Recruitment of Rural Patients in Cancer Clinical Trials

Shamsuddin Virani, Lola Burke, Scot C. Remick et al. · Journal of Oncology Practice · 2011 · 91 citations · Full text

Medicine, Oncology, Medical Oncology +15

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

Kathryn F. Mileham, Caroline Schenkel, Suanna S. Bruinooge et al. · Cancer Medicine · 2021 · 51 citations · Full text

Medicine, Oncology, Medical Oncology +14

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)

Angela R. Bradbury, Ju‐Whei Lee, Jill B. Gaieski et al. · Cancer · 2021 · 15 citations · Full text

Medicine, Genetics, Oncology +17

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer

Patricia A. Ganz, Hanna Bandos, Tanja Španić et al. · Journal of Clinical Oncology · 2024 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17